Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Pierre A. MORGON is Chief Executive Officer of MRGN Advisors, a consultancy dedicated to the healthcare sector, and Regional Partner for Switzerland at Mérieux Développement, an evergreen investment structure focused on medical devices, in vitro diagnostics and patient management services. Chairman of the Board of Virometix, a company developing proprietary synthetic nanoparticle platform in vaccines and immunotherapeutic drugs for viral diseases and cancer. He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD, IMD and MCE executive programs. Board positions: Non-Executive Director to the Board of Theradiag, a company focusing on in vitro diagnostics in auto-immunity, infectious diseases and allergy. Non-Executive Director to the Board of Eurocine Vaccines, a company dedicated to developing intra nasal vaccines.
The vaccine segment is anticipated to be one of the fastest growing one of the healthcare industry and several leading firms have stepped up vaccine investments in recent years. Unlike therapeutic agents, vaccines are administered to healthy individuals only once or very infrequently during a life time. Vaccines generate well-documented positive externalities, yet their poor awareness and acceptability among vaccine end-users may contribute to resurgence of transmissible diseases and consequently trigger governmental interventions such as mandating vaccination. In addition to technical and clinical development per the highest quality standards, bringing new vaccines to market requires carefully orchestrated programs targeting the multiple types of stakeholders along the entire value chain and addressing their respective purchasing behavioral drivers. Against a backdrop of anti-vaccination buzz and vaccine fatigue, successful global launch and sustainable usage of a vaccine requires the development of a multi-pronged strategy addressing all aspects in relation to acceptability (e.g. the motivation to immunize despite the quasi-disappearance of the disease), accessibility (e.g. supply chain services), availability (e.g. mechanisms ensuring reliability of supply) and affordability (e.g. tiered pricing policy taking country differences in per capita income into account). Leveraging novel technological advances can positively influence the ability to activate these levers successfully